Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies.
Rosenson
Robert S
RS
Department of Cardiovascular Medicine, University of Michigan Health System, Ann Arbor, MI 48109-5853, USA. rrosenso@umich.edu
Pitt
Bertram
B
D054058:Acute Coronary Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D002995:Clofibric Acid / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D014280:Triglycerides / Q000097:blood*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014280:Triglycerides; D002995:Clofibric Acid